| Project/Area Number |
18H02913
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 56010:Neurosurgery-related
|
|---|
| Research Institution | Kagawa University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
小川 大輔 香川大学, 医学部附属病院, 助教 (70524057)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥16,380,000 (Direct Cost: ¥12,600,000、Indirect Cost: ¥3,780,000)
Fiscal Year 2020: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2019: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2018: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
|
|---|
| Keywords | Glioblastoma / (pro)renin receptor / molecular therapy / glioma / antibody / Wnt/β-catenin pathway / glioma stem cell / gliomagenesis / glioblastoma / pro-renin receptor / (pro)Renin receptor / proRenin receptor / proRenin Receptor / (pro)Renin Receptor |
|---|
| Outline of Final Research Achievements |
The prognosis of Glioblastoma (GBM) patients remains one of the worst among all the malignat tumors. Therefore, a novel therapeutic method has been long waited. We report that the pro-renin receptor is related in tumorigenesis of GBM by mediating one of the most important part of Wnt/beta catenin pathway. Hence, by silencing pro-renin receptor, we have successfully suppressed glioblastoma tumorigenesis. Now, this time we have developed the antibody for Glioblastoma, so we planed to seek if this antibody works as a brand new therapy for Glioblastoma.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究計画においては、（P)RRが神経膠腫において真新しい治療ターゲットと成り得ることを示す内容となっており、本研究計画の(p)RRに対する抗体療法は抗腫瘍効果が見込まれ、新規がん治療の分子ターゲットと成り得る。その結果、膠芽腫の早期発見による、初期段階で治療が開始されることで、患者生命予後の改善および、医療費削減にも貢献することができる。このことから本研究から得られる成果は、社会的に極めて大きなインパクトを与えると想定される。
|
